SS-31 (Elamipretide): Forzinity, Mitochondrial Evidence and Safety Limits

SS-31 is no longer only a research-peptide code. The same compound is elamipretide, and the FDA-approved drug product is Forzinity. In September 2025, FDA granted Forzinity accelerated approval for a narrow rare-disease use: improving muscle strength in adults and pediatric patients with Barth syndrome who weigh at least 30 kg.

That approval matters because many peptide-market pages still describe SS-31 as a general mitochondrial optimizer, anti-aging peptide, exercise booster or fatigue peptide. The evidence is more specific. Elamipretide has a serious clinical development record in mitochondrial disease, but the approved claim is not a broad wellness claim.

For PeptideStat context, compare this guide with MOTS-c, what peptides are, tesamorelin, the longevity peptide category, and peptide half-life explained. If you are reading vial or injection content online, also review peptide storage and how to inject peptides safely for general safety concepts.

This guide is educational and not medical advice. Forzinity is a prescription drug with a defined FDA label. SS-31 products sold outside regulated channels should not be treated as equivalent to Forzinity or as a substitute for clinician-supervised rare-disease care.

SS-31 At A Glance

What SS-31 Is

SS-31 is a short peptide designed to localize to mitochondria. The Forzinity label describes elamipretide as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function.

That sentence is the cleanest mechanism summary, but it should not be inflated. Mitochondria appear in nearly every online wellness topic because they are central to energy metabolism. A compound with mitochondrial effects in disease models does not automatically become a treatment for normal aging, burnout, training fatigue, kidney disease or exercise performance.

Elamipretide's development program is more clinical than most peptide-market compounds. It has randomized trials, long-term open-label data, FDA advisory committee history and a regulated label. The hard part is reading those data without turning a rare-disease drug into a universal mitochondrial supplement.

What FDA Approved

FDA granted accelerated approval to Forzinity on September 19, 2025. The approved indication is to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

Barth syndrome is an ultra-rare X-linked mitochondrial disorder that can involve cardiomyopathy, skeletal myopathy, exercise intolerance, fatigue, growth problems and neutropenia. It is not the same clinical problem as ordinary tiredness or age-related performance decline.

The accelerated approval path is also important. FDA's Drug Trials Snapshot states that Forzinity was approved based on an increase in knee extensor muscle strength observed in a clinical trial. FDA also states that a significant difference was not shown during the initial randomized portion for the primary endpoints of 6-minute walk distance and fatigue score, while increases were observed during the longer open-label period.

That is a nuanced approval, not a simple "trial proved everything" story. FDA is requiring a post-approval randomized, double-blind, placebo-controlled trial to verify that the muscle-strength change translates into clinical benefit.

Evidence By Use Case

Barth Syndrome Trial Context

The published Barth syndrome trial was a phase 2/3 randomized, double-blind, placebo-controlled crossover study followed by an open-label extension. It enrolled a very small number of participants, which is expected in an ultra-rare disease but still affects how strongly the results can be generalized.

The FDA approval also relied on longer-term open-label observations. Open-label extension data can be valuable in rare diseases, especially when there are few patients and limited alternatives. It is still less protected against bias than a large blinded trial because everyone knows the drug is being given.

The practical reading is balanced:

• Forzinity is FDA-approved for a specific Barth syndrome population.
• The approval is meaningful for a serious rare disease with unmet need.
• It is accelerated approval, not traditional approval after confirmed clinical benefit.
• The evidence should not be repackaged as proof of broad SS-31 wellness use.

Primary Mitochondrial Myopathy Data

Primary mitochondrial myopathy, or PMM, is another area where elamipretide has been studied in humans. The early MMPOWER dose-escalation trial and the MMPOWER-2 crossover trial reported signals around walking distance, fatigue or symptom measures. Those studies helped explain continued interest.

The larger MMPOWER-3 randomized clinical trial is the cautionary counterweight. Its PubMed abstract classifies the evidence as showing that elamipretide did not improve the 6-minute walk test or fatigue at 24 weeks compared with placebo in patients with primary mitochondrial myopathy.

That matters for readers comparing SS-31 claims. A smaller positive signal does not guarantee a larger phase 3 success. Mitochondrial diseases are heterogeneous, trial endpoints are hard, and disease biology may differ by genotype. A post hoc analysis has explored genotype-specific effects, but post hoc subgroup work is hypothesis-generating unless confirmed prospectively.

Safety And Label Limits

Forzinity is a regulated product, and the label is more useful than peptide forum anecdotes for basic risk framing.

The most common adverse reactions in the prescribing information are injection-site reactions. The label also lists serious hypersensitivity as a contraindication and warning area. It warns about benzyl alcohol toxicity and states that Forzinity should not be used in neonates. Pediatric use has been established only for Barth syndrome patients weighing at least 30 kg.

The label also states that adults with severe renal impairment need a reduced dose, while patients with renal failure on dialysis were not studied. Those details show why a "mitochondrial peptide" frame is not enough. Kidney function, product formulation, age, weight, diagnosis and route all matter.

Research-grade SS-31 adds another layer. A vial sold online may not match Forzinity's formulation, manufacturing controls, sterility, concentration, excipient profile, storage requirements or patient instructions. A certificate of analysis does not turn a research chemical into an FDA-approved drug.

How To Read SS-31 Claims

Reddit and forums are useful for discovering what people ask about: daily injections, fatigue, kidney disease, stacking with MOTS-c, trial access, cost and source quality. They are not evidence that SS-31 works for those uses.

Where SS-31 Fits

SS-31 sits in an unusual evidence tier. It is more clinically developed than many research peptides because elamipretide has a regulated product and published human trials. It is still not a broad anti-aging or performance compound.

That makes it different from MOTS-c, where human data are mostly endogenous-level and exercise-measurement studies, and from AOD-9604, where fat-loss marketing outruns human outcome support. It is also different from tesamorelin, which has a separate approved label for HIV-associated visceral abdominal fat.

The most accurate current summary is:

• SS-31 is elamipretide.
• Forzinity is FDA-approved under accelerated approval for a narrow Barth syndrome indication.
• The approval depends on an intermediate muscle-strength endpoint and a required confirmatory trial.
• PMM evidence is mixed, with a larger phase 3 trial not meeting key endpoints.
• General anti-aging, kidney, endurance and "energy" claims remain unestablished.

Bottom Line

SS-31 deserves a more serious reading than many peptide-market compounds because elamipretide has an FDA-approved drug product and a human clinical trial record. The approval is real, current and important for Barth syndrome.

The limit is just as important. Forzinity's label does not validate SS-31 as a general mitochondrial enhancer, anti-aging peptide, fatigue treatment or athletic-performance tool. Readers should separate the approved rare-disease drug from unregulated research products and from broad mitochondrial marketing.

References

1. FDA. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome.

2. DailyMed. Forzinity elamipretide hydrochloride injection prescribing information.

3. FDA. Drug Trials Snapshots: Forzinity.

4. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

5. Thompson WR, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

6. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.

7. Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.

8. Karaa A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

9. Hirano M, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

10. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects.